Casimersen (Amondys 45) for Duchenne Muscular Dystrophy (online only)

Date:  June 28, 2021 Issue #:  1627 Summary:  Casimersen (Amondys 45 – Sarepta), an IV antisense oligonucleotide, has received accelerated approval from the FDA for treatment of Duchenne muscular dystrophy (DMD) in patients who have mutations of the dystrophin gene that are amenable to exon 45 skipping (DMD-45), which occur in ~8% of DMD cases. …

Casimersen (Amondys 45) for Duchenne Muscular Dystrophy (online only) Read More »